Expanding the definition and classification of hypertension.

Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. Med Clin North Am (2009) 1.59

MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond) (2014) 0.98

New and old mechanisms associated with hypertension in the elderly. Int J Hypertens (2011) 0.87

Comprehensive cardiovascular risk management--what does it mean in practice? Vasc Health Risk Manag (2007) 0.86

Hypertension in hemodialysis patients: an opinion-based update. Semin Dial (2014) 0.85

Associations between arterial elasticity and markers of inflammation in healthy older women. J Gerontol A Biol Sci Med Sci (2012) 0.81

Impact of Septal Correction on the Blood Pressure of Hypertensive Patients with Deviated Nasal Septum. Indian J Otolaryngol Head Neck Surg (2015) 0.81

Beyond type 2 diabetes, obesity and hypertension: an axis including sleep apnea, left ventricular hypertrophy, endothelial dysfunction, and aortic stiffness among Mexican Americans in Starr County, Texas. Cardiovasc Diabetol (2016) 0.79

Prevalence and determinants of pre-hypertension and hypertension among the adults in rural Bangladesh: findings from a community-based study. BMC Public Health (2015) 0.79

Blood pressure control and cardiovascular risk reduction. Hippokratia (2007) 0.78

Rationale for multiple risk intervention: the need to move from theory to practice. Vasc Health Risk Manag (2007) 0.77

Reversion of left ventricle remodeling in spontaneously hypertensive rats by valsartan is associated with the inhibition of caspase-3, -8 and -9 activities. Biomed Rep (2015) 0.76

Normotensive offspring of hypertensive Nigerians have increased left ventricular mass and abnormal geometric patterns. Pan Afr Med J (2012) 0.76

On redefining hypertension. Tex Heart Inst J (2010) 0.75

Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (2005) 0.75

Evaluation of Autonomic Dysfunction in Obese and Non-Obese Hypertensive Subjects. J Clin Diagn Res (2016) 0.75

Hypertension: definitions and guidelines. J Clin Hypertens (Greenwich) (2005) 0.75

Brain natriuretic peptide as a potential novel marker of salt-sensitivity in chronic kidney disease patients without cardiac dysfunction. Heart Vessels (2016) 0.75

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52

Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44

Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med (2011) 11.11

Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06

Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40

Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73

Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 7.48

Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03

Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation (2007) 5.20

The prognostic value of a nomogram for exercise capacity in women. N Engl J Med (2005) 5.03

Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72

Exercise capacity and the risk of death in women: the St James Women Take Heart Project. Circulation (2003) 4.19

Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11

Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91

Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71

Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68

Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. Endocr Pract (2012) 3.27

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet (2010) 3.16

Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol (2011) 2.83

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56

Meta-analysis of statin effects in women versus men. J Am Coll Cardiol (2012) 2.56

Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51

Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation (2007) 2.50

Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med (2009) 2.48

Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension (2008) 2.44

Flow-induced vascular remodeling in the mouse: a model for carotid intima-media thickening. Arterioscler Thromb Vasc Biol (2003) 2.44

Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol (2011) 2.40

Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation (2003) 2.36

Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation (2002) 2.35

Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res (2003) 2.33

J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J (2010) 2.32

Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med (2009) 2.24

Glutathiolation regulates tumor necrosis factor-alpha-induced caspase-3 cleavage and apoptosis: key role for glutaredoxin in the death pathway. Circ Res (2006) 2.24

The multifunctional GIT family of proteins. J Cell Sci (2006) 2.24

Strain-dependent vascular remodeling: the "Glagov phenomenon" is genetically determined. Circulation (2004) 2.21

Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol (2008) 2.17

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet (2003) 2.10

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J (2004) 2.09

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 2.06

Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. Am Heart J (2013) 2.05

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02

Comprehensive stroke centers overcome the weekend versus weekday gap in stroke treatment and mortality. Stroke (2011) 2.01

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99

ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97

Blood pressure measurement reliability among different racial-ethnic groups in a stroke prevention study. Blood Press Monit (2014) 1.97

Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol (2002) 1.94

Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation (2002) 1.93

Heart rate response to exercise stress testing in asymptomatic women: the st. James women take heart project. Circulation (2010) 1.93

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res (2009) 1.93

C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation (2005) 1.92

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens (2004) 1.90

Flow antagonizes TNF-alpha signaling in endothelial cells by inhibiting caspase-dependent PKC zeta processing. Circ Res (2007) 1.87

Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res (2006) 1.86

Augmentation index and central aortic stiffness in middle-aged to elderly individuals. Am J Hypertens (2007) 1.85

Fluid shear stress activates proline-rich tyrosine kinase via reactive oxygen species-dependent pathway. Arterioscler Thromb Vasc Biol (2002) 1.79

Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest (2005) 1.77

Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail (2003) 1.77

Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol (2007) 1.76

Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension (2010) 1.74

Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem (2006) 1.74

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2006) 1.73

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73

Low-fat dietary pattern and lipoprotein risk factors: the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2010) 1.73

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension (2006) 1.71

Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension (2011) 1.69

Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. Circulation (2006) 1.67

Big mitogen-activated protein kinase (BMK1)/ERK5 protects endothelial cells from apoptosis. Circ Res (2003) 1.66

Bcr kinase activation by angiotensin II inhibits peroxisome-proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells. Circ Res (2008) 1.63

Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail (2013) 1.61

Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol (2004) 1.61

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens (2004) 1.60

The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in flow-induced PPARgamma activation in endothelial cells. Mol Cell Biol (2004) 1.59

Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59

Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. J Hypertens (2007) 1.59

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol (2002) 1.58

Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem (2002) 1.57

Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail (2004) 1.57

Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation (2004) 1.56

Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol (2006) 1.54

Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res (2003) 1.54

Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. Stroke (2008) 1.53